Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative dienogest versus GnRH agonist versus no treatment for prevention of endometriosis recurrence
ChiCTR2000029375Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Zhengzhou University
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dienogest in endometriosis (3 arms), sponsored by The Third Affiliated Hospital of Zhengzhou University. Primary endpoint: VAS score. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
dienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on ChiCTR2000029375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029375.